Genedata, a leading provider of advanced software solutions for R&D, today announced that the MyBio consortium has chosen Genedata Selector® as its genome management and characterization platform to support its highly innovative R&D work in antibiotics. MyBio is an interdisciplinary consortia combining industrial leaders like BASF with several leading academic research institutions and is co-funded by the German Federal Ministry of Education and Research (BMBF). The goal of the project is to establish an innovative approach for deriving industrial polyketides by applying precise genome editing in the context of systems as well as synthetic biology. Genedata will be responsible for managing and analyzing all experimental data and integrating multi-omics based workflows for the design and modelling of Streptomyces strains.
The future of antibiotics - With resistance on the rise, the demand for innovative antibiotics is rapidly increasing. However, the actual number of new antibiotics reaching the market has substantially decreased over the last ten years. This is due to long-lead times for research and development, inefficiencies in production leading to low yields, and low margins in the market place. It seems that it is currently not economically viable for the pharma industry to devote significant resources to the research and development of antibiotics. Unless market conditions change, or new innovative models of pharmaceutical development can be applied, the number of active antibiotic research programs will continue to fall.
This is where MyBio hopes to make an impact. The MyBio consortium will develop a genetically altered producer organism for pamamycin, a proprietary polyketide of the consortium. They will focus on sustainable production from renewable supply chains. The project intends to establish a novel high-tech Streptomyces-based production platform technology including everything from carefully planned cycles of systems-level analysis and modelling to optimized fermentation and down-stream production for scale-up. Pamamycin will be the first test to prove this process is viable and can be applied to future productions of polyketides.
“Genedata’s contribution is a major component of the MyBio project,” said Prof Dr. Christoph Wittman, MyBio’s project coordinator. “Standardized, highly automated data processing as provided by Genedata Selector is paramount to the success of this endeavor as it provides the foundation of information for efficient strain design. Genedata Selector is also the obvious choice due to its centralized data integration capabilities, as well as its included collaboration and decision support.”
Genedata Selector enables the integration of genotype and phenotype information and facilitates the target identification for metabolic engineering projects. Designed for scientists, lab personal, process engineers and project managers, Genedata Selector:
“We are excited about our collaboration with the MyBio consortium. It further validates Genedata Selector’s capabilities in strain design and optimization of economically relevant bioprocesses,” noted Dr. Othmar Pfannes, CEO of Genedata. “Genedata remains committed to supporting innovative research projects in academic and industrial partnerships with its scalable and flexible bioinformatics platforms.”
MyBio brings together a consortium of leading experts from academic research in systems biology (Center for Biotechnology, Genomics-Technology Platform, Bielefeld University), synthetic biology (Pharmaceutical Biolotechnology Universität des Saarlandes), metabolic engineering (Institute of Systems Biotechnology Universität des Saarlandes), a high-tech company specializing in bioinformatics solutions (Genedata GmbH) and the world’s largest chemical company (BASF SE) to develop an innovative value chain for the fermentative production of polyketides.
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D.
Follow Us on LinkedIn
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.